Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now early-phase tilt small index

Recurrent Colorectal Carcinoma: early-phase trial registry

1 of 6 indexed Recurrent Colorectal Carcinoma trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #2,866 of 28,707 conditions by registered trial count.

6 US clinical trials · 1 currently recruiting · #2,866 of 28,707 conditions by registered trial count

Recurrent Colorectal Carcinoma: 6 US clinical trials tracked, 1 recruiting.

Recurrent Colorectal Carcinoma is the subject of 6 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 3 of these trials.

Enrollment posture brief

Registry condition recurrent-colorectal-carcinoma

OPEN 1 | RECR 17% | LATE 0 | EARLY 5 | RANK #2866 | SPON 3

Nearest open-share peer: Acute Renal Failure (17% recruiting · 6 trials)

Acute Hypoxemic Respiratory 66.7%Abdominal Aortic Aneurysms50%Acupuncture50%Acute Lymphoblastic Leukemia50%Recurrent Colorectal Car (th…17%
Open-enrollment share among volume-matched conditions near Recurrent Colorectal Carcinoma

Recurrent Colorectal Carcinoma lists 1 open slots (17% of 6 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Recurrent Colorectal Carcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Recurrent Colorectal Carcinoma is recruiting below its size-band peers.

    1 of 6 indexed trials (16.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Recurrent Colorectal Carcinoma research.

    M.D. Anderson Cancer Center accounts for 3 of 6 trials (50%). 4 distinct sponsors appear on at least one study for this condition label.

  3. Most Recurrent Colorectal Carcinoma trials plan to enrol fewer than 100 people.

    Median target enrolment is 46 among the 6 trials that report a genuine target (sentinel values excluded). 4 of those (66.7%) plan for fewer than 100 participants.

  4. Recurrent Colorectal Carcinoma research is mostly interventional.

    6 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 13Phase 22

Phase Distribution

PhaseTrial count
Phase 1 3
Phase 2 2

Named interventions

Most-linked intervention names on Recurrent Colorectal Carcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Laboratory Biomarker Analysis Other
3 trials
Cetuximab Biological
2 trials
ERK1/2 Inhibitor LY3214996 Drug
1 trials
Rintatolimod Drug
1 trials
Pharmacological Study Other
1 trials
Recombinant Interferon Alfa-2b Biological
1 trials
Health Telemonitoring Other
1 trials
Encorafenib Drug
1 trials

US sites by state

Facility locations filed on Recurrent Colorectal Carcinoma trials. A trial with sites in several states counts in each.

Texas 4 trials
New York 2 trials
North Carolina 2 trials
California 2 trials
Rhode Island 1 trials
Pennsylvania 1 trials
Ohio 1 trials
New Jersey 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Recurrent Colorectal Carcinoma page

6 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Recurrent Colorectal Carcinoma condition card totals 6 registered trials; most-linked intervention Laboratory Biomarker Analysis; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.